Breast implant illness (BII) is a collection of systemic symptoms that some people develop after getting breast implants, whether for cosmetic or reconstructive purposes. It is not a single disease with a clear diagnostic test but rather a pattern of widespread symptoms, most commonly fatigue, joint pain, and cognitive difficulties, that patients and a growing number of physicians attribute to the body’s reaction to the implant. The FDA now requires breast implant labels to include a warning that implants “have been associated with systemic symptoms,” and a large meta-analysis of over 1,000 patients found that roughly 82% reported symptom improvement after having their implants removed.
Common Symptoms
BII symptoms are whole-body rather than localized to the chest. Based on FDA medical device reports, the most frequently reported symptoms are:
- Fatigue: reported in about 41% of cases
- Joint pain or joint issues: about 31%
- Anxiety: about 23%
- Autoimmune-related symptoms or diagnoses: about 23%
- Brain fog: about 23%
- Hair loss: about 20%
- General feelings of illness: about 19%
- Depression: about 17%
- Rash: about 17%
- Unexplained weight changes: about 17%
Many people with BII describe a slow accumulation of symptoms rather than a sudden onset. The timeline varies widely. Some notice changes within months of implantation, while others go years before symptoms appear. Research suggests BII symptoms may not emerge within the first three years but could develop later, which makes the connection harder to recognize. It’s common for people to visit multiple specialists for fatigue, joint pain, or cognitive issues before considering their implants as a possible cause.
Why It Happens
There is no single proven mechanism for BII, but the leading scientific framework is called ASIA syndrome, short for autoimmune/inflammatory syndrome induced by adjuvants. First described in 2011, ASIA proposes that certain substances (adjuvants) can overstimulate the immune system in genetically susceptible people. Silicone, the material in most breast implants, acts as one of these adjuvants.
The theory works like this: silicone triggers chronic low-level immune activation, pushing the body to produce inflammatory signals continuously. Over time, this sustained immune response may cause the body to start attacking its own tissues, a process called molecular mimicry. The result is a cascade of inflammation that produces the widespread, seemingly unrelated symptoms people with BII experience. Not everyone with implants develops this response, which suggests that individual genetic predisposition plays a significant role.
How BII Differs From BIA-ALCL
BII is sometimes confused with breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), but they are very different conditions. BIA-ALCL is a rare cancer of the immune system. Its symptoms are localized: persistent swelling around the implant, a mass near the breast, or pain at the implant site. It is diagnosed through lab analysis of fluid or tissue samples taken from around the implant, tested for specific cancer markers.
BIA-ALCL occurs almost exclusively with textured implants. Smooth implants carry essentially no risk for this cancer. BII, by contrast, has been reported with all implant types, both textured and smooth, silicone and saline. The FDA’s boxed warning covers both conditions but distinguishes between them: BIA-ALCL is a cancer requiring specific oncological treatment, while BII is a pattern of systemic symptoms.
How BII Is Diagnosed
There is no blood test or scan that confirms BII. Instead, diagnosis is a process of exclusion. Doctors typically run bloodwork to check for autoimmune conditions, thyroid disorders, and other diseases that could explain the symptoms. Imaging, usually MRI or ultrasound, is used to check implant integrity and rule out rupture, which can cause its own set of problems. If a silicone implant has ruptured and is leaking, that can worsen or mimic BII symptoms.
The strongest clue is the pattern itself: multiple systemic symptoms that developed after implantation, don’t have another clear explanation, and don’t respond well to standard treatments. Many patients describe years of inconclusive test results before a physician considers the implants as a contributing factor.
Treatment Through Implant Removal
The primary treatment for BII is explantation, the surgical removal of the implants. A systematic review and meta-analysis covering 1,073 patients who had their implants removed for systemic symptoms found that 81.9% reported improvement afterward, with an average symptom reduction of about 55%. Fatigue improved most often (58% of patients), followed by joint pain (51%) and muscle pain (44%).
There are two main surgical approaches. A standard capsulectomy involves opening the scar tissue capsule that naturally forms around any implant, removing the implant, and then removing the capsule tissue separately. An en bloc capsulectomy removes the implant and the entire surrounding capsule as one intact piece, without opening it. The en bloc method is preferred when an implant has ruptured or when there is concern about BIA-ALCL, because it prevents any material inside the capsule from contacting surrounding tissue. For BII specifically, many patients and surgeons favor en bloc removal, though a standard capsulectomy is sometimes necessary when the capsule has fused to the chest wall or ribs.
Researchers believe that removing the implants works by eliminating the source of chronic immune stimulation. Without the silicone acting as a constant trigger, the body’s inflammatory response can wind down, autoantibody production decreases, and the immune system gradually rebalances. Recovery timelines vary. Some people feel noticeably better within weeks, while for others the improvement is gradual over months.
What the FDA Requires
The FDA now recommends that all breast implant packaging include a boxed warning, the most prominent type of safety notice. The warning must inform patients that breast implants are not lifetime devices, that the chance of complications increases over time, that some complications will require additional surgery, and that implants have been associated with both BIA-ALCL and systemic symptoms. This labeling change, introduced in 2020, reflected growing recognition that BII represents a real clinical pattern, even as the precise biological mechanisms continue to be studied.
The inclusion of systemic symptoms in mandatory labeling was a significant shift. For years, many patients reported that their concerns about implant-related illness were dismissed. The FDA’s decision to require this warning validated what thousands of patients had been describing and gave physicians a clearer framework for discussing these risks before surgery.